- Danish stocks
- Norwegian stocks
- Swedish stocks
- AktieTorget
- A1M Pharma
- Accelerator Nordic
- AlphaHelix
- AroCell
- Biotech-IgG
- Brighter
- Clinical Laserthermia
- Emotra
- Enzymtica
- Eurocine Vaccines
- European Inst. of Science
- IDL Biotech
- Medfield Diagnostics
- MedicPen
- MediRox
- MediRätt
- Micropos Medical
- PharmaLundensis
- Respiratorius
- Rubicon Life Science
- SensoDetect
- WntResearch
- Orasolv
- Senzime
- SPAGO Imaging
- Vivoline Medical
- First North Stockholm
- OMX Stockholm A-F
- OMX Stockholm G-Z
- AktieTorget
- US stocks
- General discussion
- All posts
The Opposition. What to expect?
Opposition Division is a “control institution” at the EPO.
OD’s job is to check complaints about patents, that the “opposer” claims not to be in line with EPO rules and regulations.
A patent has to comply to 3 things.
1: Novelty. 2: Inventive Steps. 3: Applicable.
If a patent doens’t meet all of these terms, a patent can’t be grated.
If a patent is granted, and an opponent finds that “new matter” determines that a patent is conflicting with this “new matter” an opposition can be made.
Hence this case.
Statistics says that 33% of all proprietors get their patent send back to examining division, 33% get a “new patent” with altered content, and 33% maintain their patent unchanged.
But as the medico/biotech sector in a larger degree suffers from Opposition cases, I find it safe to claim that the 33%*3 isn’t applicable, as it is “easy” to test the patent in regards to the 3 rules in mention.
In regards to OD’s notice that they find the opposition to be justified, you have to remember, that naturally they find ALL accepted oppositions to be justified. Otherwise they reject the opposition outright. Nevertheless 33% maintain their patent AFTER unchanged an OD oral proceeding.
And OD is right, the CUT-OFF patent is conflicting with certain points. IF Bioporto is able to adjust their patent in order to comply with the 3 rules, without adding new material, OD should issue the new patent, with the amended claims.
And just as closing remark …. In the oppostion filed by Abbott, they makes it clear that they DEMAND that they will recieve financial compensation if Bioporto file additional studies during the opposition trials….. (after which Abbott have the nerve to send in close to 400 pages the very week before the oral proceedings) … Thats a great sense of humor.
About Karl M. Bidstrup
Tidligere ejer af Medicoinvestor.com Strategien har gennem mange år været at profitere på etablerede aktier, og brænde det hele af på Bioporto... Sad but true. Kontakt mig på medicoinvestor(A)gmail.com hvis du har en million du ikke ved hvor du skal gemme, så skal jeg nok holde den for dig. 🙂
- Web |
- More Posts(101)
No related posts.
3 Responses to The Opposition. What to expect?
Leave a Reply Cancel reply
Ongoing debate
- Lesliejek on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Patrickciz on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Jameskipse on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- Rickiehiela on Chat transcript regarding the NGAL distr. Agreement with the Wiener Group. (In danish)
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
Bragesnak tror jeg man kalder det 🙂
det er en besynderlig optræden fra Abbott – de virker smaskfornærmede over at man ikke bare ligger sig på ryggen – opgiver patentet – og kompenserer Abbott for ulejligheden.
Men der ser man jo tit – jo færre realiteter jo mere bravalla. Jeg har ikke fantasi til at forestille mig at Abbott – der j HAR tabt sagn et par gange – har held til at tromle EPO ned. For man skal jo huske – at det jo ikke er BioP der har tildelt sig selv et patent – det er den europæiske patent organisation. Modparten i denne sag er derfor i virkeligheden ikke BioPorto – men EPO…
Synes det er en fin statistik. 1/3 chance for at indsigelserne afvises efter oral proceedings. (omend den nok er noget mindre end 33%, nu hvor OD har udtalt sig så klart) 1/3 chance for at patentets udstedelse inddrages, og vi ryger tilbage i EPO's examining division, og endelig 1/3 chance for at patentet underves bliver ændret så at det overholder reglerne. (Det er med overvejende sandsynlighed her vi ender)
Bør man være bekymret for statistikken?. Tænker på Wiki om EPO under statistik